|
|
Biotech
|
|
||
Lite snips$OCUL Piper maintains Overweight, PT lowered to $8 from $13 : Cowen Downgrades Ocular Therapeutix $OCUL to Market Perform PT $3 :Downgraded to Outperform from Strong Buy at Raymond James, PT $5 from $11 $SESN Sesen Bio Announces Acceptance of Analytical Comparability Plan by the U.S. Food and Drug Administration to Support the BLA and Commercialization of Its Lead Asset, Vicinium® for Non-Muscle Invasive Bladder Cancer $BCRX BCX7353 Meets Primary Endpoint in Phase 3 APeX-2 Trial . |
return to message board, top of board |
Msg # | Subject | Author | Recs | Date Posted |
27361 | Re: Lite snips | minxmrphd | 7 | 5/21/2019 8:05:42 AM |